Science China Life Sciences

, Volume 56, Issue 6, pp 495–502 | Cite as

A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered

  • Yi Rao
  • RunHong Li
  • DaQing Zhang
Open Access


It is surprising that, while arsenic trioxide (ATO) is now considered as “the single most active agent in patients with acute promyelocytic leukemia (APL)”, the most important discoverer remains obscure and his original papers have not been cited by a single English paper. The discovery was made during the Cultural Revolution when most Chinese scientists and doctors struggled to survive. Beginning with recipes from a countryside practitioner that were vague in applicable diseases, Zhang TingDong and colleagues proposed in the 1970s that a single chemical in the recipe is most effective and that its target is APL. More than 20 years of work by Zhang and colleagues eliminated the confusions about whether and how ATO can be used effectively. Other researchers, first in China and then in the West, followed his lead. Retrospective analysis of data from his own group proved that APL was indeed the most sensitive target. Removal of a trace amount of mercury chloride from the recipe by another group in his hospital proved that only ATO was required. Publication of Western replication in 1998 made the therapy widely accepted, though neither Western, nor Chinese authors of English papers on ATO cited Zhang’s papers in the 1970s. This article focuses on the early papers of Zhang, but also suggests it worth further work to validate Chinese reports of ATO treatment of other cancers, and infers that some findings published in Chinese journals are of considerable value to patients and that doctors from other countries can benefit from the clinical experience of Chinese doctors with the largest population of patients.


leukemia arsenic trioxide acute promyelocytic leukemia 


  1. 1.
    Ellison R R, Holland J F, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood, 1968, 32: 507–523PubMedGoogle Scholar
  2. 2.
    Boiron M, Weil M, Jacquillat C, et al. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet, 1969, 293: 330–333CrossRefGoogle Scholar
  3. 3.
    Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood, 1973, 41: 489–496PubMedGoogle Scholar
  4. 4.
    Bernard J, Weil M, Jacquillat C I. Treatment of acute granulocytic leukemias. Ann Rev Med, 1974, 25: 39–50PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang T D, Zhang P F, Wang S R, et al. Preliminary clinical observations of six cases of leukemia treated by “Ailin solution” (in Chinese) 1). Med Pharm Heilongjiang, 1973, (3): 66–67Google Scholar
  6. 6.
    Departments of Traditional Chinese Medicine and Laboratory Medicine of the First Affiliated Hospital of Harbin Medical University. Therapeutic observations of 17 cases leukemia treated with Ailin No.1 and dialectic theory (in Chinese). J Harbin Med Univ, 1974, (2): 25–30Google Scholar
  7. 7.
    Rong F X, Zhang T D. A report on long term survival of two cases of acute granulocytic leukemia (in Chinese). J New Med Pharm, 1979, (6): 31–34Google Scholar
  8. 8.
    Zhang T D, Rong F X. Treatment of acute granulocytic leukemia by Ailin No.1 and dialectic theory (in Chinese). Med Pharm Heilongjiang, 1979, (4): 7–11Google Scholar
  9. 9.
    Huang M E, Ye Y C, Chen S R, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia: report of six cases (in Chinese). Chin Med J, 1987, 100: 949–953PubMedGoogle Scholar
  10. 10.
    Huang M E, Ye Y C, Chen S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72: 567–572PubMedGoogle Scholar
  11. 11.
    Sanz M A, Grimwade D, Tallman M S, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2009, 113: 1875–1891PubMedCrossRefGoogle Scholar
  12. 12.
    Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood, 2009, 114: 51260–51235CrossRefGoogle Scholar
  13. 13.
    Sanz M A, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol, 2011, 29: 495–503PubMedCrossRefGoogle Scholar
  14. 14.
    Powell B L, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116: 3751–3757PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Estey E H. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center. J Clin Oncol, 2011, 29: 2743–2746PubMedCrossRefGoogle Scholar
  16. 16.
    Sears D A. History of the treatment of chronic myelocytic leukemia. Am J Med Sci, 1988, 296: 85–86PubMedCrossRefGoogle Scholar
  17. 17.
    Jolliffe D M. A history of the use of arsenicals in man. J Royal Soc Med, 1993, 86: 287–289Google Scholar
  18. 18.
    Guan J R. Leukemia: clinical analysis of 49 cases (in Chinese). Heilongjiang Med, 1958, (2): 22–34Google Scholar
  19. 19.
    Gu D X. Preliminary observations of the therapeutic effect of the traditional Chinese medicine “55” on leukemia (in Chinese). Harbin J Trad Chin Med, 1964, 5: 24Google Scholar
  20. 20.
    Chaoyang People’s Hospital Department of Pediatrics. Experience of using a combination of arsenic and chemotherapy to treat leukemia (in Chinese). Anti-Cancer Battle News of Liaoning (internally circulated materials, be careful in safekeeping, by the Office of Cancer Prevention and Treatment Research of Liaoning Province), 1972, (7): 23–24Google Scholar
  21. 21.
    Hematology Group of the Department of Internal Medicine at Xiyuan Hospital of the Chinese Academy of Traditional Medicine. Treatment of leukemia by traditional Chinese medicine (in Chinese). Guangdong Med, 1974, (5): 31–37Google Scholar
  22. 22.
    Zhou A X. Research on Qinghuang San treatment of leukemia (in Chinese). Chin J Integrat Trad West Med, 1998, 18: 582–583Google Scholar
  23. 23.
    Department of Traditional Chinese Medicine of the First Affiliated Hospital of Harbin Medical University (Supervisor: Zhang T D. Writers: Li Y S, Hu X C. Participants: Li M X, Zhang P F, Rong F X, et al.). A clinical summary of 73 cases treated by Ailin No.1 combined with the dialectic theory (in Chinese). Chin Med Pharm Heilongjiang, 1981, (4): 28–30Google Scholar
  24. 24.
    Zhang T D. Comments on questions about designing clinical research with combined Chinese and Western medicine (in Chinese). J Integrat Trad Chin West Med, 1982, 2: 180–181Google Scholar
  25. 25.
    Zhang T D. Understanding and treatment of leukemia by Chinese medicine (in Chinese). J Trad Chin Med, 1983, (3): 71–74Google Scholar
  26. 26.
    Zhang T D, Li Y S. Clinical findings and experimental research of Ailin No. 1 in treating acute granuloleukemia (in Chinese). J Integrat Trad Chin West Med, 1984, 4: 19–20Google Scholar
  27. 27.
    Zhang T D. Diagnosis and treatment of acute non-lymphatic leukemia (in Chinese). J Integrat Trad Chin West Med, 1985, 5: 713Google Scholar
  28. 28.
    Sun H D, Ma L, Hu X C, et al. A report on 16 acute promyelocytic leukemia cases of long term survival treated by Ailin No.1 in combination with traditional Chinese dialectic theories (in Chinese). Inf Trad Chin Med Pharm, 1991, (6): 39–41Google Scholar
  29. 29.
    Sun H D, Ma L, Hu X C, et al. Ailin I treated 32 cases of acute promyelocytic leukemia (in Chinese). Chin J Integrat Chin West Med, 1992, 12: 170–172Google Scholar
  30. 30.
    Zhang P, Wang S Y, Hu L H, et al. “713” (As2O3) treatment of 117 cases of acute promyelocytic leukemia: clinical observations and mechanistic investigations (in Chinese). J Harbin Med Univ, 1995, 29: 243Google Scholar
  31. 31.
    Zhang P, Wang S Y, Hu L H, et al. Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide (in Chinese). Chin J Hematol, 1996, 17: 58–62Google Scholar
  32. 32.
    Collins S J, Gallo R C, Gallagher R E. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature, 1977, 270: 347–349PubMedCrossRefGoogle Scholar
  33. 33.
    Breitman T R, Selonick S E, Collins S J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA, 1980, 70: 2936–2940CrossRefGoogle Scholar
  34. 34.
    Breitman T R, Collins S J, Keene B R. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood, 1981, 57: 1000–1004PubMedGoogle Scholar
  35. 35.
    Olsson I L, Breitman T R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′: 5′-monophosphate-inducing agents. C Cancer Res, 1982, 42: 3924–3927Google Scholar
  36. 36.
    Honma Y, Fujita Y, Kasukabe T, et al. Induction of differentiation of human acute non-lymphocytic leukemia cells in primary culture by inducers of differentiation of human myeloid leukemia cell line HL-60. Eur J Cancer Clin Oncol, 1983, 19: 251–261PubMedCrossRefGoogle Scholar
  37. 37.
    Koeffler H P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood, 1983, 62: 709–721PubMedGoogle Scholar
  38. 38.
    Flynn P, Miller W, Weisdorf D, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood, 1983, 62: 1211–1217PubMedGoogle Scholar
  39. 39.
    Nilsson B. Probable in vivo induction of differentiation by retinoic acid acid of promyelocytes in acute promyelocytic leukemia. British J Haematol, 1984, 57: 365–371CrossRefGoogle Scholar
  40. 40.
    Daenen S, Vellenga E, van Dobbenbugh O A, et al. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood, 1986, 67: 559–561PubMedGoogle Scholar
  41. 41.
    Fontana J A, Roger I S, Durham J P. The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer, 1986, 57: 209–217PubMedCrossRefGoogle Scholar
  42. 42.
    Chomienne C, Ballerini P, Balitrand N, et al. Retinoic acid therapy for promyelocytic leukemia. Lancet, 1989, 334: 746–747CrossRefGoogle Scholar
  43. 43.
    Castaigne S, Chomienne C, Daniel M T, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 1990, 76: 1704–1709PubMedGoogle Scholar
  44. 44.
    Chen Z X, Xue Y Q, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood, 1991, 78: 1413–1419PubMedGoogle Scholar
  45. 45.
    Warrell Jr R P, Frankel S T, Miller Jr W H, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med, 1991, 324: 1385–1393PubMedCrossRefGoogle Scholar
  46. 46.
    Tallman M S, Andersen J W, Schiffer C A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997, 337: 1021–1028PubMedCrossRefGoogle Scholar
  47. 47.
    Duan J X, Xin X M, Wang F Q, et al. Anti-cancer effect of Ailin No. 1 on leukemic cells of acute promyelocytic leukemia patients (in Chinese). Pract J Oncol, 1992, (2): 29–30Google Scholar
  48. 48.
    Huang S L, Guo A X, Xiang Y, et al. Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets (in Chinese). Chin J Hematol, 1995, 16: 26Google Scholar
  49. 49.
    Chen G Q, Zhu J, Shi X G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 1996, 88: 1052–1061PubMedGoogle Scholar
  50. 50.
    Xu J S, Duan J M, Xu Y, et al. A case of APL survival of 20 years with treatment by Ailin I (in Chinese). Chin J Hematol, 1997, 18: 476Google Scholar
  51. 51.
    Chen G Q, Shi X G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345–3353PubMedGoogle Scholar
  52. 52.
    Shen Z X, Chen G Q, Ni J H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89: 3354–3360PubMedGoogle Scholar
  53. 53.
    Soignet S L, Maslak P, Wang Z G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339: 1341–1348PubMedCrossRefGoogle Scholar
  54. 54.
    Rosenthal E. Chairman Mao’s cure for cancer. New York Times, May 6th, 2001Google Scholar
  55. 55.
    Chen G Q, Chen S J, Wang Z Y, et al. (1998). Mechanisms and prospects of arsenic treatment of acute promyelocytic leukemia (in Chinese). Chin J Integrat Trad Chin West Med, 1998, 18: 581–582Google Scholar
  56. 56.
    Mervis J. Cancer research: ancient remedy performs new tricks. Science, 1996, 273: 578PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang T D, Chen G Q, Wang Z G, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene, 2001, 20: 7146–7153PubMedCrossRefGoogle Scholar
  58. 58.
    Zhu J, Chen Z, Lallemand-Breitenbach V, et al. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer, 2001, 2: 705–714CrossRefGoogle Scholar
  59. 59.
    Wang Z Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111: 2505–2515PubMedCrossRefGoogle Scholar
  60. 60.
    Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94: 3315–3324PubMedGoogle Scholar
  61. 61.
    Chen S J, Zhou G B, Zhang X W, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117: 6425–6437PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Zhang P. The history of discovering arsenic trioxide (in Chinese)., 2013Google Scholar
  63. 63.
    Au W Y, Kumana C R, Lee H K K, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood, 2011, 118: 6535–6543PubMedCrossRefGoogle Scholar
  64. 64.
    Li Y S, Zhang T D, Wang X R, et al. Investigation of the dynamics of Ailin No. 1 on human liver cancer cells (in Chinese). Res Cancer Prevent Treat, 1988, 15: 1–3Google Scholar
  65. 65.
    Liu L X, Zhu A L, Chen W, et al. Effect of arsenic trioxide on hepatocellular carcinoma and its mechanistic studies. Chin J Surg, 2005, 43: 33–36PubMedGoogle Scholar
  66. 66.
    Guo H X, Chen W, Liu L X, et al. Recent status of the effect of arsenic trioxide on colon cancer. Chin J Integr Trad West Med Dig, 2006, 14: 207–209Google Scholar

Copyright information

© The Author(s) 2013

Authors and Affiliations

  1. 1.Peking-Tsinghua Center for Life Sciences at Peking University School of Life SciencesBeijingChina
  2. 2.Peking University Health Sciences CenterBeijingChina

Personalised recommendations